Vifor Pharma Group increases equity stake in ChemoCentryx from 6.6% to 21.2%. Vifor Pharma Group acquires an additional 7,343,492 common shares of ChemoCentryx, Inc. (NASDAQ: CCXI) from...

Vifor Pharma today announced the launch of an inaugural Swiss Franc straight bond in the amount of CHF 465 million in the Swiss domestic market. The bond carries a 0.75% fixed coupon with a tenor...

Strong financial performance in H1 2018 Three medium-term strategic growth drivers fully on track #Strategic in-licensing deal concluded with Cara Therapeutics Inc Net sales and EBITDA guidance...

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to develop and commercialise CR845/difelikefalin injection worldwide except in the US, Japan and South Korea for the treatment of chronic kidney...

All proposals of the Board of Directors approved by shareholders Election of Jacques Theurillat to the Board of Directors Re-election of standing members of the Board of Directors Dividend of CHF...